Stay updated on Pembrolizumab for EGFR+ NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab for EGFR+ NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab for EGFR+ NSCLC Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedAdded a new Locations section with California as a listed site and updated the revision from v3.3.2 to v3.3.3. The old California Locations link and the HHS Vulnerability Disclosure have been removed.SummaryDifference0.2%

- Check19 days agoNo Change Detected
- Check26 days agoNo Change Detected
- Check34 days agoChange DetectedThe page now displays a revision label 'Revision: v3.3.2' replacing the previous 'Revision: v3.3.1'.SummaryDifference0.1%

- Check41 days agoChange DetectedPublications section now clarifies PubMed as the source of auto-filled articles and that they may not pertain to the study. The page revision tag has been updated to v3.3.1.SummaryDifference0.1%

- Check48 days agoChange DetectedA site-wide funding/operating status notice was removed. This does not modify the study details, eligibility criteria, or results displayed on the page.SummaryDifference0.4%

- Check62 days agoChange DetectedNo significant changes detected between the old and new screenshots; the page content and structure appear the same. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check91 days agoChange DetectedUpdate adds a government-funding status notice and NIH Clinical Center operating details with a v3.2.0 revision, while removing the old v3.1.0 tag.SummaryDifference3%

Stay in the know with updates to Pembrolizumab for EGFR+ NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for EGFR+ NSCLC Clinical Trial page.